<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02099994</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-CORE 004/IAVI N004</org_study_id>
    <nct_id>NCT02099994</nct_id>
  </id_info>
  <brief_title>Safety &amp; Immunogenicity of HIV Vaccines in Healthy Kenyan Adults</brief_title>
  <acronym>HIV-CORE 004</acronym>
  <official_title>A Phase I/IIa Clinical Trial of HIV-1 Vaccines pSG2.HIVconsv DNA, MVA.HIVconsv and Ad35-GRIN in Combined Regimens in Healthy HIV-1/2-negative Adults in Nairobi.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oxford</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European and Developing Countries Clinical Trials Partnership (EDCTP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>International AIDS Vaccine Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ichor Medical Systems Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oxford</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is part of a long-term aim to develop an effective HIV-1 vaccine and will evaluate&#xD;
      safety and immunogenicity of vaccines focusing T cell responses on the conserved region of&#xD;
      the HIV-1 proteome. The vaccines used are pSG2.HIVconsv DNA (D), MVA.HIVconsv (M) and&#xD;
      Ad35-GRIN (A), delivered in regimens AM, DDDAM and DeDeDeAM, where e indicates&#xD;
      electroporation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objectives of this study are to determine the vaccines' safety and immunogenicity in&#xD;
      an African population, and further strengthen the vaccine trial capacity in the South.&#xD;
&#xD;
      HIV-CORE 004 is a double blind, placebo controlled randomized Phase I/IIa study designed to&#xD;
      evaluate the safety and immunogenicity of different delivery regimens using three novel HIV-1&#xD;
      vaccines pSG2.HIVconsv DNA (D) with and without electroporation (e), adenovirus Ad35-GRIN (A)&#xD;
      and poxvirus MVA.HIVconsv (M) administered by intramuscular needle injection in heterologous&#xD;
      prime-boost regimens.&#xD;
&#xD;
      72 healthy, low-risk, HIV-1-uninfected adult volunteers in Nairobi will be randomly assigned&#xD;
      to one of three groups, AM, DDDAM and DeDeDeAM each containing 20 vaccinees and 4 placebo&#xD;
      recipients.&#xD;
&#xD;
      Firstly, this study aims to evaluate the safety and tolerability of the vaccines&#xD;
      pSG2.HIVconsv DNA (D) with and without electroporation (e), adenovirus Ad35-GRIN (A) and&#xD;
      poxvirus MVA.HIVconsv (M).&#xD;
&#xD;
      Secondly, we shall determine the effect of electroporation during DNA priming on the&#xD;
      frequency, durability and/or quality of T cell responses (DDDAM vs DeDeDeAM).&#xD;
&#xD;
      Thirdly, we shall determine whether priming with three DNA vaccinations with or without&#xD;
      electroporation affects the frequency, durability and/or quality of T cell responses to the&#xD;
      HIVconsv immunogen compared to that seen in the AM regimen (AM vs DDDAM/DeDeDeAM).&#xD;
&#xD;
      As this is the first study of the combined HIVconsv vaccines in an African population, of the&#xD;
      pSG2.HIVconsv DNA with electroporation, and the combination of the two HIVconsv vaccines with&#xD;
      Ad35-GRIN, this trial has been designed as a pilot study to compare different vector&#xD;
      combinations. The sample sizes will only allow detection of large response differences&#xD;
      between volunteers in the three groups, thus, yielding data that are primarily descriptive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Safety</measure>
    <time_frame>44 weeks</time_frame>
    <description>Proportion of volunteers who develop a grade 3 or 4 local reaction. Proportion of volunteers who develop a grade 3 or 4 systemic reaction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaccine immunogenicity</measure>
    <time_frame>44 weeks</time_frame>
    <description>T cell responses will be determined initially by interferon-gamma enzyme-linked immunospot assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine Safety</measure>
    <time_frame>44 weeks</time_frame>
    <description>A descriptive summary of grade 3 of 4 local and systemic events including laboratory abnormalities.&#xD;
A descriptive summary of serious adverse events, including laboratory abnormalities</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>AIDS</condition>
  <arm_group>
    <arm_group_label>A - AM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad35-GRIN 5 x 10^10 vp IM at week 0, MVA.HIVconsv 2 x 10^8 pfu IM at week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - DDDAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pSG2.HIVconsv DNA 4 mg or saline placebo at weeks 0, 4 and 8. Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - DeDeDeAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electroporated pSG2.HIVconsv 4 mg or electroporated saline placebo at weeks 0, 4 and 8.&#xD;
Ad35-GRIN 5 x 10^10 vp or saline placebo at week 12. MVA.HIVconsv 2 x 10^8 pfu or saline placebo at week 20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad35-GRIN</intervention_name>
    <description>intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo</description>
    <arm_group_label>A - AM</arm_group_label>
    <arm_group_label>B - DDDAM</arm_group_label>
    <arm_group_label>C - DeDeDeAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA.HIVconsv</intervention_name>
    <description>IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo</description>
    <arm_group_label>A - AM</arm_group_label>
    <arm_group_label>B - DDDAM</arm_group_label>
    <arm_group_label>C - DeDeDeAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pSG2.HIVconsv DNA</intervention_name>
    <description>IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo</description>
    <arm_group_label>B - DDDAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Electroporated pSG2.HIVconsv</intervention_name>
    <description>IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo</description>
    <arm_group_label>C - DeDeDeAM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adults aged 18-50&#xD;
&#xD;
          -  Willing to comply with the requirements of the protocol and available for follow-up&#xD;
             for the planned duration of the study.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Willing to undergo HIV-1 testing, counselling and receive test results.&#xD;
&#xD;
          -  All female volunteers must be willing to undergo urine pregnancy tests&#xD;
&#xD;
          -  If sexually active using an effective method of contraception until at least 4 months&#xD;
             after the last vaccination.&#xD;
&#xD;
          -  Willing to forgo donating blood during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any relevant abnormality on history or examination including history of&#xD;
             immunodeficiency or autoimmune disease, or use of systemic corticosteroids,&#xD;
             immunosuppressive, antiviral, anticancer or other medication that, in the opinion of&#xD;
             the Principal Investigator or designee, is clinically significant, within the previous&#xD;
             6 months. (Note: use of inhaled steroids for asthma or use of topical steroids for&#xD;
             localized skin conditions will not exclude a volunteer from participation.)&#xD;
&#xD;
          -  Any clinically significant acute or chronic medical condition that is considered&#xD;
             progressive or, in the opinion of the Principal Investigator or designee, would make&#xD;
             the volunteer unsuitable for the study.&#xD;
&#xD;
          -  Any of the following abnormal laboratory parameters (1 abnormal test may be repeated&#xD;
             once if thought to be due to a temporary condition):&#xD;
&#xD;
               -  Haematology&#xD;
&#xD;
                    -  Haemoglobin &lt; 9.0 g/dl for women and &lt;11.0 g/dl for men&#xD;
&#xD;
                    -  Absolute Neutrophil Count (ANC) ≤ 1000 /mm3 (≤ 1 x 109 /l)&#xD;
&#xD;
                    -  Absolute Lymphocyte Count (ALC) ≤ 600 /mm3 (≤0.6 x 109 /l)&#xD;
&#xD;
                    -  Platelets ≤100,000 /mm3, ≥ 550,000 /mm3 (≤ 100 /l, ≥ 550 /l)&#xD;
&#xD;
               -  Biochemistry&#xD;
&#xD;
                    -  Creatinine &gt; 1.3 x upper limit of normal (ULN)&#xD;
&#xD;
                    -  Aspartate aminotransferase (AST) &gt; 2.5 x ULN&#xD;
&#xD;
                    -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN&#xD;
&#xD;
               -  Urinalysis- Clinically significant abnormal dipstick confirmed by microscopy:&#xD;
&#xD;
                    -  Protein = 2+ or more&#xD;
&#xD;
                    -  Blood = 2+ or more (for women: before or after menses)&#xD;
&#xD;
          -  Confirmed HIV-1 or HIV-2 infection.&#xD;
&#xD;
          -  If female, pregnant or planning a pregnancy any time from enrolment to 4 months after&#xD;
             the last vaccination; or lactating.&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within the previous 60 days or planned receipt at&#xD;
             any time until 60 days after vaccination with Investigational Medicinal Product (IMP)&#xD;
             or receipt of other vaccine, including influenza vaccine, within the previous 14 days&#xD;
             or planned receipt at any time until 14 days after vaccination with the IMP.&#xD;
&#xD;
          -  Receipt of blood transfusion or blood products within the previous 6 months.&#xD;
&#xD;
          -  Participation in another clinical trial of an IMP currently or within the previous 3&#xD;
             months or expected participation during this study.&#xD;
&#xD;
          -  Receipt of any investigational HIV-1 vaccine within the last 6 years.&#xD;
&#xD;
          -  History of severe or very severe local or systemic reactogenicity events after&#xD;
             vaccination, or history of severe or very severe allergic reactions.&#xD;
&#xD;
          -  Confirmed diagnosis of acute or chronic hepatitis B virus infection (spontaneous&#xD;
             clearance leading to natural immunity, indicated by antibodies to core + antigens, is&#xD;
             not an exclusion criterion); confirmed diagnosis of hepatitis C virus infection;&#xD;
             untreated syphilis.&#xD;
&#xD;
          -  Smallpox vaccination within the previous 3 years.&#xD;
&#xD;
          -  Major psychiatric illness in the previous 3 years.&#xD;
&#xD;
          -  History of allergy or hypersensitivity to latex, chronic skin problems such as eczema&#xD;
             or psoriasis, or skin and subcutaneous tissue thickness &gt; 40 mm as assessed by skin&#xD;
             pinch test in either deltoid region.&#xD;
&#xD;
          -  Presence of an implantable device&#xD;
&#xD;
          -  Current use of any electronic stimulation device. Therapeutic or traumatic metal&#xD;
             implant in either deltoid region.&#xD;
&#xD;
          -  History of, or known active cardiac disease or a heart condition under the care of a&#xD;
             doctor. Note: Slight physiological variation of normal resting heart rate (60 - 100&#xD;
             beats/minute) with respiration is NOT excluded.&#xD;
&#xD;
          -  History of syncope or fainting episode within 1 year of study entry.&#xD;
&#xD;
          -  Seizure disorder or any history of prior seizure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Walter Jaoko</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nairobi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KAVI-Kangemi clinic</name>
      <address>
        <city>Nairobi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>March 26, 2014</study_first_submitted>
  <study_first_submitted_qc>March 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2014</study_first_posted>
  <last_update_submitted>May 27, 2016</last_update_submitted>
  <last_update_submitted_qc>May 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>vaccine</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

